Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;7(1):e000430.
doi: 10.1136/lupus-2020-000430.

Candidate drug replacements for quinacrine in cutaneous lupus erythematosus

Daisy Yan  1   2 , Robert Borucki  1   2 , Richard D Sontheimer  3 , Victoria P Werth  4   2
Affiliations
Review

Candidate drug replacements for quinacrine in cutaneous lupus erythematosus

Daisy Yan et al. Lupus Sci Med. 2020 Oct.

Abstract

Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.

Keywords: autoimmune diseases; lupus erythematosus; methotrexate; systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DY, RB and RDS have nothing to disclose. VPW reports personal fees from Genentech, Medimmune, Amgen, Resolve, Lilly, Principia, BMS, AC, Nektar, EMD Serona, Astra Zeneca, Vielo, Abbvie, Kyowa Kirin, GSK and Cugene, outside the submitted work; grants and personal fees from Biogen, Gilead, Celgene and Janssen; in addition, VPW has patents Cutaneous Lupus Erythematous Disease Area and Severity Index and CDASI with royalties paid.

References

    1. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011;64:849–58. 10.1016/j.jaad.2010.02.008 - DOI - PMC - PubMed
    1. Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981;20:57–60. 10.1111/j.1365-4362.1981.tb05295.x - DOI - PubMed
    1. Mittal L, Werth VP. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol 2017;77:374–7. 10.1016/j.jaad.2017.03.027 - DOI - PMC - PubMed
    1. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007;20:160–74. 10.1111/j.1529-8019.2007.00131.x - DOI - PMC - PubMed
    1. Cardoso EC, Pereira NZ, Mitsunari GE, et al. TLR7/TLR8 activation restores defective cytokine secretion by myeloid dendritic cells but not by plasmacytoid dendritic cells in HIV-infected pregnant women and newborns. PLoS One 2013;8:e67036. 10.1371/journal.pone.0067036 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources